MENU
Anatomy
Anesthesiology
Biochemistry
Biomedical Informatics
Biophysics
Cell Biology
Clinical Cases
Dentistry
Dermatovenerology
Emergency Medicine
Family Medicine
Forensic Medicine
Gynecology and Obstetrics
Histology and Embryology
History of Medicine
Human Genetics
Hygiene
Infectious Diseases
Internal Medicine
Medical Deontology and Philosophy
Medical Psychology
Microbiology and Immunology
Neurology
Occupational Medicine
Oncology
Ophthalmology
Orthopaedics
Otorhinolaryngology
Pathology
Pathophysiology
Pediatrics
Pharmacology and Experimental Toxicology
Physical and Rehabilitation Medicine
Physiology
Psychiatry
Radiology
Social Medicine
Surgery
Toxicology
Research papers
Clinical research paper
Preclinical research paper
Sponsored articles
Archive » 2012 » 3-4 » | Archive » Medical field » Fields » Pharmacology and Experimental Toxicology »

Antiasthmatic Drugs

 
Abstract:

This post is also available in: enEnglish slSlovenščina (Slovenian)

The incidence of bronchial asthma is very high in paediatric as well as in the adult population. Nevertheless, life style changes and adequate pharmacotherapy enables asthma patients to live normal, healthy life. If the disease is mild the drugs are usually taken by inhalations, while for more severe form of disease systemic application of drugs either oral or by injecting is necessary. Anti-asthma drugs are divided into two groups: controllers, which prevent asthma attacks and healers that are applied when the disease deteriorates. Pharmacological classification divides anti-asthma drugs into bronchodilators (adrenergic agonists, xantines, cisteninyl-leukotriene antagonists, antimuscarinic drugs), anti-inflammatory drugs (corticosteroids) and biologic drugs (omalizumab).

Authors:
Kržan Mojca

Keywords:
asthma, pharmacotherapy, bronchodilators, antiinflammatory drugs

Cite as:
Med Razgl. 2012; 51: 433–45.
© 2021 Društvo Medicinski razgledi | Na vrh strani / To top ↑